Infelctra®/CT-P13* has robust clinical data for switching patients from Remicade®† to Inflectra®/CT- P13*17,39,41-43,46,47,53-55

EU and UK guidance supports switching from reference biologics to a biosimilar in appropriate patients13,57,59,60

Decisions regarding treatment choice or physician-mediated switching must be a clinical decision made by a treating physician on an individual patient basis, supported by scientific evidence, and with patient awareness.

Watch the video to discover more about the Potential Benefits of Switching to a Biosimilar:

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

Click here to read about NOR-SWITCH Trial
Click here to read about Study 3.4

*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.

 

 

PP-IFA-GBR-0310. December 2018